These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38744451)

  • 1. Characteristics and rates of infection by HIV in people receiving non-occupational post-exposure prophylaxis (nPEP) against HIV.
    Carrillo I; López de Las Heras M; Martínez SC; Prieto-Pérez L; Álvarez Álvarez B; Waleed Al-Hayani A; Suarez-Inclan JI; Fernandez SL; Luengo PQ; Diaz MEA; Bernal Palacios M; Mathews PA; Bonafont BS; Bravo Ruiz R; Hernández-Segurado M; Górgolas M; Cabello A
    Sex Transm Infect; 2024 May; 100(4):231-235. PubMed ID: 38744451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
    McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
    HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Adherence to HIV Post-Exposure Prophylaxis and Retention in Care After an Episode of Sexual Violence in Brazil.
    Nisida IVV; Boulos MC; da Silva LMB; Mayaud P; Avelino-Silva VI; Segurado AC
    AIDS Patient Care STDS; 2019 Sep; 33(9):399-405. PubMed ID: 31386552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic.
    Gulholm T; Jamani S; Poynten IM; Templeton DJ
    Sex Health; 2013 Nov; 10(5):438-41. PubMed ID: 23962489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to HIV post-exposure prophylaxis: A multivariate regression analysis of a 5 years prospective cohort.
    Malinverni S; Gennotte AF; Schuster M; De Wit S; Mols P; Libois A
    J Infect; 2018 Jan; 76(1):78-85. PubMed ID: 29074102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
    Malinverni S; Bédoret F; Bartiaux M; Gilles C; De Wit S; Libois A
    Sex Transm Infect; 2021 Aug; 97(5):329-333. PubMed ID: 33106437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
    Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
    BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonoccupational post-exposure prophylaxis for HIV after sexual intercourse among women in Brazil: Risk profiles and predictors of loss to follow-up.
    Grangeiro A; Nascimento MMPD; Zucchi EM; Ferraz D; Escuder MM; Arruda É; Lotufo D; Munhoz R; Couto MT
    Medicine (Baltimore); 2019 Sep; 98(39):e17071. PubMed ID: 31574806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
    Mayer KH; Mimiaga MJ; Cohen D; Grasso C; Bill R; Van Derwarker R; Fisher A
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):494-9. PubMed ID: 18176318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing non-occupational post-exposure prophylaxis drug regimens for HIV: insights from a linked HIV surveillance system.
    Pierce AB; El-Hayek C; McCarthy D; Armishaw J; Watson K; Wilkinson A; Price B; Wright EJ; Hoy JF; Stoové MA
    Sex Health; 2017 Apr; 14(2):179-187. PubMed ID: 27914484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription of Non-Occupational Post-Exposure HIV Prophylaxis by Emergency Physicians: An Analysis on Accuracy of Prescription and Compliance.
    Malinverni S; Libois A; Gennotte AF; La Morté C; Mols P
    PLoS One; 2016; 11(4):e0153021. PubMed ID: 27070319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and effectiveness of HIV non-occupational prophylaxis in Taiwan.
    Li HC; Cheng YP; Yang CJ
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19736. PubMed ID: 25397481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.
    Valin N; Fonquernie L; Daguenel A; Campa P; Anthony T; Guiguet M; Girard PM; Meyohas MC
    BMC Infect Dis; 2016 Nov; 16(1):718. PubMed ID: 27894270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standardizing HIV post-exposure prophylaxis in the emergency department following sexual assault.
    Silva-Nash J; Bordelon S; Searcy SA; Dare RK
    HIV Med; 2022 Mar; 23(3):268-273. PubMed ID: 34725910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of HIV non-occupational post-exposure prophylaxis for men who have sex with men in 2 cities of Southwestern China.
    Wu Y; Zhu Q; Zhou Y; Liang S; Li R; Liang N; Li C; Lan G
    Medicine (Baltimore); 2021 Oct; 100(43):e27563. PubMed ID: 34713829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: results from South-Eastern France.
    Rey D; Bendiane MK; Bouhnik AD; Almeda J; Moatti JP; Carrieri MP
    AIDS Care; 2008 May; 20(5):537-41. PubMed ID: 18484321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics, sexual practices and sexually transmissible infections diagnoses of men who have sex with men and use non-occupational HIV post-exposure prophylaxis in Victoria, Australia.
    Ong JJ; Landika A; Fairley CK; Bradshaw C; Chen M; Read TRH; Chow EPF
    Sex Health; 2016 Nov; 13(6):555-559. PubMed ID: 27537936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Post-Exposure Prophylaxis (PEP) Awareness and Non-Occupational PEP (nPEP) Prescribing History Among U.S. Healthcare Providers.
    John SA; Quinn KG; Pleuhs B; Walsh JL; Petroll AE
    AIDS Behav; 2020 Nov; 24(11):3124-3131. PubMed ID: 32300991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in HIV post-exposure prophylaxis prescriptions before and after the introduction of HIV pre-exposure prophylaxis at a sexual health clinic in Melbourne, Australia, 2011-2021.
    Samra RS; Fairley CK; Ong JJ; Aung ET; Chow EP
    Aust N Z J Public Health; 2024 Aug; 48(4):100179. PubMed ID: 39053109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.